Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:BLU

BELLUS Health (BLU) Stock Price, News & Analysis

BELLUS Health logo

About BELLUS Health Stock (NASDAQ:BLU)

Advanced Chart

Key Stats

Today's Range
$14.74
$14.75
50-Day Range
$14.42
$14.75
52-Week Range
$6.38
$14.76
Volume
3.45 million shs
Average Volume
3.08 million shs
Market Capitalization
$1.87 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. BELLUS Health Inc. was incorporated in 1993 and is based in Laval, Canada. As of June 28, 2023, BELLUS Health Inc. operates as a subsidiary of GSK plc.

Receive BLU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BELLUS Health and its competitors with MarketBeat's FREE daily newsletter.

BLU Stock News Headlines

What President Trump’s Executive Order 14154 means for your money
Nearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a former hedge fund manager who predicted the dotcom crash, the housing crisis, and the 2022 tech stock bloodbath - a little-known executive order from the President's first day in office could spark a paradigm-shift that will likely catch millions of Americans off guard.
See More Headlines

BLU Stock Analysis - Frequently Asked Questions

BELLUS Health Inc. (NASDAQ:BLU) released its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by $0.07. BELLUS Health had a negative net margin of 578,586.63% and a negative trailing twelve-month return on equity of 24.27%.

Based on aggregate information from My MarketBeat watchlists, some other companies that BELLUS Health investors own include NIO (NIO), Meta Platforms (META), Pfizer (PFE), Sorrento Therapeutics (SRNE), Alibaba Group (BABA), Tesla (TSLA) and Ford Motor (F).

Company Calendar

Last Earnings
11/10/2021
Today
5/01/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:BLU
Employees
74
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-76,080,000.00
Net Margins
-578,586.63%
Pretax Margin
-578,226.56%

Debt

Sales & Book Value

Annual Sales
$15,000.00
Price / Sales
124,613.93
Price / Cash Flow
N/A
Book Value
$3.09 per share
Price / Book
4.77

Miscellaneous

Free Float
96,162,000
Market Cap
$1.87 billion
Optionable
Not Optionable
Beta
0.19
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:BLU) was last updated on 5/1/2025 by MarketBeat.com Staff
From Our Partners